It has emerged in recent months that the Sinovac vaccine, which is produced in China and also known as CoronaVac, lost its protective effect after it was applied. Thereupon, many scientists called for the application of the 3rd dose of BioNTech vaccine, and the 3rd dose vaccination campaign was started. Months passed, and a study conducted in Turkey revealed whether the idea of the 3rd dose worked.
A study conducted on healthcare professionals working at Hafsa Sultan Hospital revealed that all those who received the third dose of the vaccine had a protective amount of antibodies. Thus, it became clear that the idea of a 3rd dose, albeit only for Sinovac, makes sense and can be defined as the default dose amount.
3rd dose was successful:
1053 healthcare professionals working at Manisa Celal Bayar University Faculty of Medicine Hafsa Sultan Hospital were included in a study to see the effect of 2 doses of Sinovac and 1 dose of BioNTech. In the study, in which 2 doses of the inactivated vaccine were followed for 6 months and the result was observed after taking the 3rd dose, it was seen that the 3rd dose application fully achieved its purpose. The faculty members of the MCBÜ Faculty of Medicine, Department of Medical Microbiology, Public Health and Infectious Diseases, who conducted the study in which the disease frequency and antibody level of the participants were supervised; He made the following statements about the data they obtained:
“For those with only 2 doses of CoronaVac, the antibody protection level decreased to 56% at the third month after the second vaccine. This data has proven that the 3rd dose vaccination is a good decision. Regardless of the third dose vaccine preference, all individuals receiving the 3 doses of the vaccine have their protective antibody levels. The BioNTech vaccine administered in the third dose of vaccine showed a significant superiority in protection (both in terms of antibody level and disease status) compared to the third dose of CoronaVac vaccine. The antibody level of those who received the third dose of BioNTech was above the maximum titer that could be measured in 95% of the participants. ”
Only 44 of the participants who underwent the third dose became ill due to COVID-19. However, none of them were hospitalized and had a mild outpatient illness. It is not yet clear whether it will be necessary to add the 4th dose to this application. After the 3rd dose, the observation period, which will take a total of 6 months, can give an answer to this. Even if 1 more dose of BioNTech is judged to be necessary, it may be concluded that Sinovac is almost unnecessary.
41043
